Long Ideas - Amedisys, Inc. (AMED) reported 4Q and year-end earnings Tuesday morning, and the key highlight was the company’s 2013 EPS guidance range of $0.60-$0.70, substantially below … Continue Reading
Read nowLong Ideas - With U.S. rights to Horizant returning in full to XenoPort (XNPT) in just two months, and a number of significant developmental catalysts within the same … Continue Reading
Read nowLong Ideas - Wet macular degeneration is a chronic eye disease that causes vision loss and generally occurs later in life (50+), as blood vessels leak fluid or … Continue Reading
Read nowLong Ideas - Sarepta Therapeutics (SRPT) has become a bit of a lightning rod, with the company’s shares trading near the middle of their 52-week range (from $3.30 … Continue Reading
Read nowLong Ideas - In late November, PropThink wrote about Anthera Pharmaceuticals (ANTH), noting that the company’s lead drug candidate, blisibimod (or B-mod), has promise for the treatment of … Continue Reading
Read nowLong Ideas - Sarepta (SRPT) announced Monday that results from a non-human primate study of AVI-7288, the company’s lead drug candidate for the treatment of Marburg virus infection, … Continue Reading
Read nowMost Popular - It’s been a great week for Medicinova (MNOV) shareholders, who saw their holdings climb as much as 80% with the announcement that the company’s lead … Continue Reading
Read now